| Identifier | Return Reference | Explanation |
|---|
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| 3614 shares of AMERICAN FUNDS CAP INCOME BUILDER A CAIBX | 161,218 | 177,869 |
| 37008 shares of AMERICAN FUNDS INCOME FD OF AMERICA A AMECX | 619,779 | 620,252 |
| 7879 shares of AMERICAN GROWTH FD OF AMERICA AGTHX | 157,015 | 226,359 |
| 63090 shares of ATRICURE, INC. ATRC | 83,514 | 700,299 |
| 62226 shares of AXOGEN INC COM AXGN | 200,999 | 168,010 |
| 6702 shares of CAPITAL WORLD GROWTH INCOME CWGIX | 169,316 | 215,277 |
| 2413 shares of MAP PHARMACEUTICALS, INC. MAPP | 18,494 | 31,779 |
| 20000 shares of PROSHARES TRUST TBT | 688,466 | 361,400 |
| 10000 shares of SIRTEX MEDICAL SXMDF.PK | 50,674 | 45,540 |
| 797 shares of XENOPORT, INC. XNPT | 8,006 | 3,037 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| ENABLE INJECTIONS, LLC | 35,901 | 50,000 | |
| ENABLE UROLOGY, LLC | 81,716 | 100,000 | |
| NEURONETICS, INC. SER. D PFD | 125,000 | 138,238 | |
| NEURONETICS, INC. SER. E PFD | 300,000 | 300,000 | |
| SKYLINE VENTURE PARTNERS III, L.P. | 31,460 | 61,666 | |
| SKYLINE VENTURE QUALIFIED PURCHASERS FD II LP | 40,075 | 6,424 | |
| SUREFIRE SERIES A PREFERRED STOCK | 805,000 | 880,312 | |
| USVP ENTREPRENEUR PARTNERS VIII-B, LP | 97,765 | 96,518 | |
| ZS PHARMA, INC. SER. A PFD | 100,000 | 100,000 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Administrative Fees | 25,600 | 25,600 | ||
| ENABLE INJECTIONS LLC K1 nondeductible passthrough expense | 22 | |||
| ENABLE UROLOGY LLC K1 nondeductible passthrough expense | 4 | |||
| State or Local Filing Fees | 35 | 35 | ||
| SKYLINE VENTURE PARTNERS III LP K1 passthrough expense | 2,783 | 2,783 | ||
| SKYLINE VENTURE QUALIFIED PURCHASERS FD II LP K1 passthrough expense | 79 | 79 | ||
| USVP ENTREPRENEUR PARTNERS VIIIB LP K1 passthrough expense | 1,546 | 1,546 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| ENABLE INJECTIONS, LLC K-1 Pass-Through Share of Partnership Income/Loss | -7,311 | -7,311 | |
| ENABLE UROLOGY, LLC K-1 Pass-Through Share of Partnership Income/Loss | -12,764 | -12,764 | |
| SKYLINE VENTURE PARTNERS III, L.P. K-1 Pass-Through Share of Partnership Income/Loss | 523 | 523 | |
| USVP ENTREPRENEUR PARTNERS VIII-B, LP K-1 Pass-Through Share of Partnership Income/Loss | 100 | 100 |
| Borrower's Name | Relationship to Insider | Original Amount of Loan | Balance Due | Date of Note | Maturity Date | Repayment Terms | Interest Rate | Security Provided by Borrower | Purpose of Loan | Description of Lender Consideration | Consideration FMV |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Careguide Loan Receivable | None | 50,000 | 50,000 | 2009-12 | Note is overdue, penalty interest is being accrued | 12.0000000000 % | None | Investment | Cash | 5,000 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Philanthropic Consulting Fees | 13,000 | 13,000 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Estimated Tax for 2011 | 25,900 | 0 | 0 | 0 |